Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × olaratumab × Clear all

NCT01204710 2019-09-20

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Phase 2 Completed

123 enrolled 21 charts

Prostatic Neoplasms